Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Development of lactococcal GEM-based pneumococcal vaccines.

Sandrine A L Audouy1, Saskia van Selm, Maarten L van Roosmalen

  • 1BiOMaDe Technology Foundation, Groningen, The Netherlands.

Vaccine
|November 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bifidobacterium-driven immunoglobulin A production in pediatric patients with IgA deficiency and recurrent respiratory tract infections.

Microbiome·2026
Same author

A comparative analysis of signal peptide signatures in the bacterial cell factories Bacillus subtilis and Lactococcus lactis.

New biotechnology·2026
Same author

Assessment of antigen-specific T cell recall responses in non-human primates using a composite AIM assay.

Frontiers in immunology·2025
Same author

Human colon stem cells are the predominant epithelial responders to bacterial antigens.

Frontiers in immunology·2025
Same author

Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors.

PLoS biology·2025
Same author

Innate immunity of the gut epithelium: Blowing in the WNT?

Mucosal immunology·2025

A new nasal vaccine using killed bacteria (GEM) displaying pneumococcal proteins shows promise. This safe and affordable vaccine candidate offers significant protection against Streptococcus pneumoniae pneumonia in mice.

Area of Science:

  • Vaccinology
  • Microbial immunology
  • Biotechnology

Background:

  • Streptococcus pneumoniae causes severe pneumonia.
  • Current vaccines have limitations.
  • Novel delivery systems are needed for effective vaccines.

Purpose of the Study:

  • To develop a novel protein-based nasal vaccine against Streptococcus pneumoniae.
  • To utilize a Lactococcus lactis-derived delivery system (GEM) for vaccine antigen display.
  • To evaluate the immunogenicity and protective efficacy of the vaccine in a mouse model.

Main Methods:

  • Three pneumococcal proteins (IgA1p, PpmA, SlrA) were anchored to GEM particles via a Protein Anchor (PA) domain.
  • GEM particles induced pro-inflammatory cytokine (TNF-alpha) production and dendritic cell maturation.

Related Experiment Videos

  • Mice were intranasally immunized with SlrA-IgA1p or trivalent vaccine formulations.
  • Vaccine efficacy was assessed by protection against fatal pneumococcal pneumonia.

    • Main Results:

    • GEM particles effectively displayed pneumococcal antigens.
    • Intranasal immunization induced protective immunity without additional adjuvants.
    • Significant protection against fatal Streptococcus pneumoniae pneumonia was observed in vaccinated mice.
    • The vaccine demonstrated potential for inducing both humoral and cellular immune responses.

    Conclusions:

    • A novel GEM-based trivalent nasal vaccine against Streptococcus pneumoniae is developed.
    • The vaccine candidate is safe, easy to administer, and potentially affordable.
    • This protein-based nasal vaccine shows significant protective efficacy in a preclinical model.
    • Further development could lead to a viable alternative for pneumococcal disease prevention.